Swiss anti-infectives specialist Basilea Pharmaceutica has entered a research collaboration with U.S.-based Prokaryotics to develop a novel broad-spectrum antifungal aimed at treating severe invasive fungal infections, the companies announced on January 7th 2026.
JJP Biologics has announced positive top-line results from a Phase I clinical trial of JJP-1212, its first-in-class anti-CD89 antagonist being developed for IgA-mediated inflammatory diseases. The data validate the programme’s safety and biological activity and clear the way for Phase II studies starting later this year.
The new year at Cologne-based Disco Pharma has begun much as the old one ended: with a headline-grabbing announcement. Just weeks after closing a sizeable financing round, the company has now unveiled an equally notable collaboration with US biotech pioneer Amgen, a partnership with a potential value of up to US$618 million.
Amgen has agreed to acquire Dark Blue Therapeutics in a deal valued at up to $840 million, as the biopharmaceutical company continues to build out its early-stage oncology pipeline. The specific breakdown of the upfront payment alongside development and regulatory milestones was not disclosed in the press release.
UK-based biotech LoQus23 Therapeutics is advancing an oral small molecule targeting a fundamental genetic process in Huntington’s disease, a rare neurodegenerative disorder.
The Dutch biotech argenx has announced a planned leadership transition to be effective in May after its annual shareholder meeting. Tim Van Hauwermeiren, co-founder and long-time Chief Executive Officer, will transition from CEO to Non-Executive Director and Chairman of the Board of Directors; and Karen Massey, currently Chief Operating Officer, will assume the role of CEO and Executive Director, pending shareholder approval.
On January 4, the French pharma group Servier and the AI drug discovery Insilico Medicine announced a collaboration worth up to $888 million. Insilico will receive up to $32 million from Servier for a multi-year research and development collaboration to discover and develop oncology therapies using Insilico’s artificial intelligence (AI)-driven drug discovery platform and Servier’s cancer development expertise.
Genentech Corp. / Roche
Photo from Shawn Day on Unsplash